Abstract
The Major Histocompatibility Complex Class II locus is the primary genetic linkage to autoimmune diseases. Susceptibility to each such disease is linked to different alleles, with a few alleles showing also dominant protection. The design of vaccines for autoimmune diseases is a long sought-after goal. As knowledge about the pathogenesis of these diseases has increased, the tools for such an approach have of necessity been refined. We review below the structural essence of MHC II-linked autoimmune diseases which centers on the binding of antigenic peptides to the disease-linked MHC II proteins, and the consequent activation of cognate TCRs from pathogenic CD4+ T cells. The state of affairs in two organ-specific autoimmune diseases, type 1 diabetes, celiac disease are covered, including attempts to treat these via antigen-specific MHC II-guided measures. We offer a couple of testable suggestions as to how this approach could be improved.
Keywords: APL, autoimmunity, HLA, MHC, vaccines
Current Pharmaceutical Design
Title: Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Volume: 15 Issue: 28
Author(s): Antonis K. Moustakas and George K. Papadopoulos
Affiliation:
Keywords: APL, autoimmunity, HLA, MHC, vaccines
Abstract: The Major Histocompatibility Complex Class II locus is the primary genetic linkage to autoimmune diseases. Susceptibility to each such disease is linked to different alleles, with a few alleles showing also dominant protection. The design of vaccines for autoimmune diseases is a long sought-after goal. As knowledge about the pathogenesis of these diseases has increased, the tools for such an approach have of necessity been refined. We review below the structural essence of MHC II-linked autoimmune diseases which centers on the binding of antigenic peptides to the disease-linked MHC II proteins, and the consequent activation of cognate TCRs from pathogenic CD4+ T cells. The state of affairs in two organ-specific autoimmune diseases, type 1 diabetes, celiac disease are covered, including attempts to treat these via antigen-specific MHC II-guided measures. We offer a couple of testable suggestions as to how this approach could be improved.
Export Options
About this article
Cite this article as:
Moustakas K. Antonis and Papadopoulos K. George, Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases, Current Pharmaceutical Design 2009; 15 (28) . https://dx.doi.org/10.2174/138161209789105117
DOI https://dx.doi.org/10.2174/138161209789105117 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Discovery of Potent Bruton’s Tyrosine Kinase Inhibitors Using Ligand Based Modeling
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Sjogrens Syndrome and Lymphoma Development
Current Immunology Reviews (Discontinued) Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Parasites in Rheumatoid Arthritis: Imminent Threat or Protective Effect?
Current Rheumatology Reviews Mechanisms of Altered Cell Immunity and Cytotoxicity in COPD
Current Drug Targets The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Type I Interferon as a Target of Treatment in SLE
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Expression Profiles in Human Autoimmune Disease
Current Pharmaceutical Design Inhibitors of AP-1 and NF-κB Mediated Transcriptional Activation: Therapeutic Potential in Autoimmune Diseases and Structural Diversity
Current Medicinal Chemistry SAGE Application in Hematological Research
Current Pharmaceutical Biotechnology Genomic Strategies in Pharmacology of Asthma and Autoimmunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Signaling Pathways Associated with Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery ImmunemiR - A Database of Prioritized Immune miRNA Disease Associations and its Interactome
MicroRNA CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery